Edition:
India

Invion Ltd (IVX.AX)

IVX.AX on Australia Stock Exchange

0.01AUD
10:18am IST
Change (% chg)

$-0.00 (-7.14%)
Prev Close
$0.01
Open
$0.01
Day's High
$0.01
Day's Low
$0.01
Volume
924,428
Avg. Vol
1,393,888
52-wk High
$0.03
52-wk Low
$0.01

Summary

Name Age Since Current Position

Thian Chew

2017 Non-Executive Chairman of the Board

Gregory Collier

2017 Chief Executive Officer, Managing Director, Executive Director

Tom Coogan

2012 Chief Financial Officer

Craig Newton

2018 Chief Operating Officer

Melanie Farris

2012 Company Secretary

James Campbell

2013 Non-Executive Director

Alan Yamashita

2019 Non-Executive Director

Biographies

Name Description

Thian Chew

Mr. Thian C. Chew is Non-Executive Chairman of the Board of the Company. Mr Chew was previously an Executive Director at Goldman Sachs (Hong Kong and New York) responsible for the firm’s proprietary investments including growth capital, private equity and special situations in both private and public companies. Prior to this, he was a Consultant Project Manager to Morgan Stanley, New York. Mr Chew also held a number of positions in KPMG across Asia Pacific including Director at KPMG Consulting (Singapore and Sydney) where he led several large scale operational restructuring, post-merger transformation, and business performance improvement programs. As a Senior Manager at KPMG (Taipei and Melbourne), he led several business process re-engineering initiatives, and also performed financial and information technology audit, risk and assurance engagements across multiple industries. Mr Chew holds an MBA from the Wharton School (Palmer Scholar), MA from the Lauder Institute, University of Pennsylvania, and a Bachelor of Information Systems from Monash University. Mr Chew is an Adjunct Professor at HKUST’s MBA program and previously qualified as a chartered accountant.

Gregory Collier

Dr. Gregory R. Collier, Ph.D. is re-designated as Non-Executive Director of the Company, effective 31 October 2019. He is no longer Chief Executive Officer, Managing Director, Executive Director of the Company, effective 31 October 2019. He has more than 20 years experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialization. He has led the planning and execution of multiple commercial transactions including in and out licensing deals and M&A activities, and he has taken a drug from discovery through to regulatory approval. Prior to his commercial pharmaceutical career, Dr. Collier had an academic career resulting in over 150 peer reviewed publications, and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and also held positions at Melbourne University, Monash University and the University of Toronto. In 2010, Dr. Collier was awarded the Roche Award of Excellence for his contribution to the biotechnology industry.

Tom Coogan

Craig Newton

Mr. Craig Newton is appointed as Chief Executive Officer of the Company, effective November 1. 2019. Craig Newton joined Invion as Chief Operating Officer in April 2018. Since that time, Craig has recruited a strong and experienced clinical development team. Craig has over 30 years of experience in senior business and operational roles gained at various leading global companies including CSL, Serono UK, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals.

Melanie Farris

Ms. Melanie Farris serves as a Company Secretary of Invion Limited, formerly CBio Limited, since April 23, 2012. Ms. Farris is a Certificated Member of Chartered Secretaries Australia. She joined CBio in 2007, and prior to being appointed Company Secretary in 2012 held responsibility for investor relations and corporate affairs. Melanie has a background in marketing communications across biotechnology, investment, media and not-for-profit groups. An experienced secretary in the not-for-profit sector, Ms Farris is a Certificated Member of Chartered Secretaries Australia.

James Campbell

Dr. James A. Campbell, Ph.D., is Non-Executive Director of Invion Ltd since October 14, 2013. He served as Executive Director from August 2012 to October 14, 2013, and as Non-Executive Director from February 26, 2012 to August 2012. Dr James Campbell is a senior biotechnology executive with more than 20 years international experience in scientific research, research management, management consulting and venture capital. Dr Campbell has held research positions at the CNRS and the CSIRO. He is a principal of Gemini Biotechnology, a specialist biotechnology advisory services company advising life science companies on M&A, partnering and corporate strategy. Dr Campbell was an executive at ChemGenex Pharmaceuticals for nine years until the company was acquired in 2011. During the previous three years, Dr Campbell has also served as a director of Gemini Biotechnology, Fusion Biosciences Pty Ltd and Vitality Devices.

Alan Yamashita

Mr. Alan Yamashita is Non-Executive Director of the Company. Mr. Yamashita has more than 40 years’ experience in investment management, investment banking and alternative investment. Formerly Managing Director and Head of Asia Capital Markets at Merrill Lynch as well as a 16-year veteran of Goldman Sachs, Mr Yamashita is currently Managing Partner at Polar Ventures, a private investment firm that provides capital, strategic and operating solutions, focusing on small- to medium-sized enterprises in Asia.

Basic Compensation

Name Fiscal Year Total

Thian Chew

--

Gregory Collier

50,946

Tom Coogan

83,666

Craig Newton

--

Melanie Farris

153,186

James Campbell

150,521

Alan Yamashita

--
As Of  30 Jun 2013

Options Compensation